SHERIDAN, WYOMING – July 8, 2025 – A confluence of artificial intelligence and genomics is creating a critical inflection point for the pharmaceutical industry—offering a long-awaited opportunity to reduce adverse drug reactions, improve clinical outcomes, and restore public trust in a sector burdened by scrutiny and skepticism.
SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.
SHERIDAN, WYOMING – May 6, 2025 – In a decisive move to address one of the fastest-growing global health threats, the Global Stroke Action Coalition was launched on April 9, 2025, calling on governments worldwide to make stroke a central priority in noncommunicable disease (NCD) strategies. With the global stroke burden projected to rise by 50% over the next 25 years—claiming an estimated 100 million lives and costing USD 1.6 trillion annually—this new multi-sectoral initiative is demanding urgent, evidence-based action.